Revised EU GMP Annex 19 applies
Reference/retention sample inventory, quantities, storage, testing capability, and quality agreements.
Therapeutic biotech · expansion previewFrom quality signal
From quality signal
to defensible QA decision.
Connect deviations and OOS signals with lots, suppliers, equipment, methods, analysts, procedures, and change history. AI assembles evidence and drafts hypotheses; qualified QA retains every material decision.
Evidence-linked hypotheses · Human decision gates · US/EU GMP horizon
Investigation Intelligence Batch DS-26-118 Media MC-884 Supplier SUP-019 Change CHG-117Qualified-person review required
Connected investigation
Quality evidence across the batch lifecycle.
The QMS coordinates evidence and decisions. It does not replace LIMS, MES, ERP, pharmacovigilance, or qualified release authority.
- 01Deviation or OOS/OOTSignal, source result, specification, method, and initial assessment
- 02Batch + patient impactLot genealogy, material, equipment, site, market, and uncertainty
- 03Evidence-led investigationSupporting, contrary, and missing confirmation evidence
- 04QA dispositionAuthenticated human authority; no AI release decision
- 05CAPA + effectivenessOwners, protocol, observation period, and deliberate closure
- 06PQR / APQRRoadmap: product and process lifecycle review
Control matrix
What the expansion does—and does not—claim.
“Supported demo” means an interactive synthetic-data demonstration. Customer intended-use validation is always required.
Investigation IntelligenceSupported demo
Connected synthetic deviation/OOS story with cited hypotheses and human gates
Deviation intake and investigationConfigurable
Lot, equipment, method, analyst, supplier, SOP, and change links
CAPA and effectivenessConfigurable
Evidence-backed draft, owners, protocol, and human closure
Change / technology transferConfigurable
Quality, validation, and regulatory impact in one controlled record
Supplier / CDMO quality agreementsConfigurable
Obligations, affected products and sites, and notification deadlines
OOS/OOT Phase I/IIRoadmap
Dedicated laboratory and manufacturing-review workflow planned
Batch impact and dispositionRoadmap
AI may draft considerations; qualified QA/QP retains authority
Process validation / CPV / PQRRoadmap
Lifecycle workspace and validated manufacturing integrations planned
Pharmacovigilance and clinical safetyNot covered
Requires a separate validated safety platform
MES / EBR / LIMS / ERP executionNot covered
QMS coordinates decisions; source systems execute testing and manufacturing
Representative regulatory basis
Mapped baselines, not blanket coverage.
US therapeutic coverage references Parts 210/211 plus only applicable biologics provisions. EU coverage is use-case specific. ICH Q10 is a lifecycle model—not a certification.
United States21 CFR Parts 210/211 · applicable Parts 600–680 · Part 11 control requirements · FDA data-integrity and validation guidance
European UnionEU GMP Parts I/II · applicable Annexes 1, 2, 11, 15, 16, and 19 · ATMP Part IV only where applicable
Lifecycle modelsICH Q7, Q8, Q9, Q10, and Q12 mapped according to product and regional applicability
Biotech regulatory horizon
Prepare early. Label proposals honestly.
Binding dates get applicability-led work. Drafts and anticipated milestones get scenario planning—never overdue status.
Binding future
Draft revised EU GMP Part IV for ATMPs
Scenario map only; planned publication is not an effective date.
EU SoHO Regulation generally applies
Applicability branch for relevant upstream donor, testing, collection, release, and ATMP supply chains.
EU GMP Chapter 4, Annex 11, and new Annex 22
Closed-consultation drafts for documentation, computerized systems, and AI governance.
Anticipated dates may change. Applicability must be assessed by qualified regulatory personnel against final official text.
Expansion previewSee the evidence model.
See the evidence model.
Then validate the intended use.
Explore the synthetic investigation, review explicit boundaries, and bring one therapeutic-biotech workflow to map.